Study estimates 136.8 million U.S. adults are eligible for semaglutide, a popular therapy for diabetes, weight loss, and cardiovascular disease.
TipRanks on MSN12h
iX Biopharma’s iXB 401: A Breakthrough in Drug DeliveryX Biopharma Ltd. (SG:42C) has released an update. iX Biopharma Ltd. announced that its novel semaglutide sublingual wafer, iXB 401, achieved 20 ...
Glucagon-like peptide-1 (GLP-1) agonist are a family of medications that help manage blood sugar in patients with type 2 ...
Reducing systolic blood pressure to less than 120 mmHg lowered the risk of major cardiovascular events for most people with ...
Right now, insurance companies typically only cover the cost of semaglutide if a doctor indicates its use against type 2 ...
7hon MSNOpinion
The COVID pandemic set in motion trends with alcohol use that have persisted. Disruptions in work, school and lifestyle have ...
Your doctor broke news you didn’t want to hear: you have prediabetes, a condition where blood sugar is elevated, but not high ...
NBC Los Angeles on MSN20h
FDA weighs in on diet drug shortage, creating more confusion about compoundingAs millions patients struggled to fill their prescriptions for the new weight loss drugs, many have turned to compounded copies.
First for Women on MSN23h
NK2R: A Side-Effect-Free Ozempic Alternative for Weight LossOzempic, Wegovy and Mounjaro are often the most popular weight loss drugs. While these medications help people lose weight, ...
Since the discovery of statins and the Scandinavian Simvastatin Survival Study (4S) results three decades ago, remarkable advances have been made in the treatment of dyslipidaemia, a major risk factor ...
The FDA’s decision to allow the compounding of GLP-1 weight loss drugs could undermine its public health obligations, writes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback